--:--:--
Stockwatch Reports
…

News Reports / Technology / ACLS

ACLSAxcelis Technologies, Inc.

NasdaqGS · Technology · Mkt cap $3.0B · Avg vol 343.37K

$98.80

+8.80 (+9.77%)

Quote as of November 6, 2026, 1:14 PM ET

News Impact Report · Published November 6, 2026, 9:43 AM ET

ACLS: Axcelis Technologies Posts Q3 FY2026 Revenue of $600.7M as Shares Surge Over 8%

Share

Ticker: ACLS | Filing Type: 8-K (Items 2.02, 9.01) | Filed with the SEC on: November 5, 2026 | Current Price: $97.55 | Today's Change: +8.39%


What Happened

Axcelis Technologies filed an 8-K with the SEC on November 5, 2026, disclosing its financial results for the third quarter of fiscal year 2026 (Q3 FY2026). The company reported revenues of $600.7 million for the quarter, alongside operating income of $83.1 million and net income of $28.6 million. Earnings per share came in at $2.70 on both a basic and diluted basis. The disclosure is material because it provides the market's first official look at Axcelis's quarterly performance through the most recent period, and the stock's sharp intraday move of more than 8% suggests the results exceeded investor expectations heading into the print.


Why It Matters

For investors tracking ACLS, there are several near-term takeaways from this filing:

  • Revenue scale: At $600.7 million for a single quarter, Axcelis is demonstrating substantial top-line activity in its ion implant systems and services business.
  • Profitability gap: While operating income of $83.1 million represents a healthy operating margin (~13.8%), net income of only $28.6 million indicates a meaningful step-down between operating profit and the bottom line. Investors should watch for the full 10-Q filing to understand what drove below-the-line charges — including interest expense, taxes, or other items — that reduced net income so significantly from operating income.
  • EPS delivery: Basic and diluted EPS of $2.70 gives investors a concrete per-share earnings figure for the quarter, which will serve as a key data point for consensus-tracking and forward modeling.
  • Market reaction: The stock's +8.39% move on the day of this report suggests the market viewed this quarter favorably relative to expectations, even as the absolute share price of $97.55 remains well below the $125.00 price target noted in our existing StockWatch initiating coverage from September 24, 2026.

Analysis

The headline numbers from this 8-K filing paint a picture of a company maintaining meaningful revenue throughput in a semiconductor equipment environment that has been uneven for many peers. The $600.7 million quarterly revenue figure is a significant data point, and the market's strong positive reaction suggests the results arrived at or above what the Street had priced in.

The more nuanced story is in the relationship between operating income ($83.1M) and net income ($28.6M). The roughly $54.5 million gap between the two is notable and warrants close scrutiny when the full quarterly report becomes available. This spread could reflect tax provisions, non-cash charges, or other below-the-line items — none of which are detailed in an 8-K results announcement.

What to watch next:

  • The full 10-Q filing, which will provide the complete income statement, balance sheet, cash flow statement, and management discussion — the only place where the gap between operating and net income will be explained in detail.
  • Management's forward commentary, including any guidance for Q4 FY2026 or the full fiscal year, will be the key driver of whether today's price move is sustained.
  • Order trends and backlog, which are critical leading indicators in the capital equipment space and will give investors a clearer picture of whether this revenue level is sustainable heading into 2027.

This filing follows StockWatch's existing initiating coverage of Axcelis Technologies. Readers are encouraged to consult that prior research for broader context on the company's competitive positioning and long-term outlook.


Disclaimer

This report is prepared for informational purposes only and is based solely on data contained in or accompanying the referenced SEC filing. It does not constitute investment advice, a solicitation to buy or sell any security, or a recommendation of any kind. Readers should conduct their own due diligence and consult a qualified financial professional before making any investment decision. StockWatch and its contributors may hold positions in securities mentioned.

Existing Coverage

StockWatch has full coverage on ACLS, published 2026-09-24. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1113232/000110465926123080/tm2629011d1_8k.htm

StockWatch initiated coverage · September 24, 2026

ACLS: Axcelis Technologies — Ion Implant Leadership Faces a Cyclical Reset

Valuation has compressed sharply from peak levels. At $113.14, ACLS trades roughly 42% below its 52-week high of $193.78 while sitting about 54% above the 52-week low of $73.60. On trailing EPS of $2.97, the shares carry a P/E of approximately 38.1x, a multiple that only makes sense if the market is underwriting a meaningful earnings recovery rather than a continuation of the current run-rate. The $3.5B market cap on 30.88M shares leaves little room for execution error. **The balance sh

-12.7%

Read the full report →

-12.7%

Key Data

Last

$97.55

P&L ($)

+$7.55

P&L (%)

+8.39%

Day Range

$96.57 - $99.50

Volume

24.78K

Market Cap

$3.0B

Previous Close

$90.00

Open

$98.98

52 Week Range

$73.60 - $193.78

Shares Outstanding

30.88M

Public Float

30.69M

Average Volume

343.37K

As of November 6, 2026, 9:57 AM ET

Advertise here
Stockwatch Reports

Free stock market updates, top gainers & losers, and AI-generated stock analyses — updated daily. Real-time price movements, quotes, and coverage for German & U.S. stoc